Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars

Biocon Biologics Ltd (BBL) has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo® and Evfraxy®, biosimilars of Denosumab. Vevzuo® is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone and for the treatment of adults and skeletally mature adolescents with giant cell tumour of bone. Evfraxy® is authorized for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, for the treatment of bone loss associated with hormone ablation in men with prostate cancer, and for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. Clinical data showed that both Denosumab biosimilars have comparable safety and efficacy to the reference product. In Europe, the European Commission (EC) recently granted marketing authorisation for Biocon Biologics Denosumab biosimilars, allowing their commercialization in all European Union (EU) member states and the European Economic Area (EEA).